Top Markets
Coin of the day
20/20 Biolabs Inc. 20/20 Biolabs Inc.

20/20 Biolabs Inc.

AIDX
Rang in aandelen #33874
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company... 20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (CLIAx), a shared laboratory facility that supports diagnostic test developers in bringing products to the U.S. market. The company also delivers its cancer screening algorithm technology through a software as a service (SaaS) platform in partnership with healthcare providers and supports diagnostic startups by offering access to shared laboratory space and resources. The company was founded in 2000 and is based in Gaithersburg, Maryland.
Aandeelprijs
$0.5475
Laatst gesynchroniseerd: 2026-08-14
Marktkapitalisatie
$6.71M
Verandering (1 dag)
5.57%
Verandering (1 jaar)
-
Land
US
Handel 20/20 Biolabs Inc. (AIDX)

Categorie

P/S-ratio voor 20/20 Biolabs Inc. (AIDX)
P/S-ratio op 2026 TTM: 0
Volgens de meest recente financiële rapporten en aandelenkoers van 20/20 Biolabs Inc. is de huidige P/S-ratio (TTM) 0. Eind 2026 had het bedrijf een P/S-ratio van 0.
P/S-ratiohistoriek voor 20/20 Biolabs Inc. van 2026 tot 2026
P/S-ratio aan het einde van elk jaar
Jaar P/S-ratio Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
P/S-ratio voor vergelijkbare bedrijven of concurrenten